Please login to the form below

Not currently logged in
Email:
Password:

J&J’s COVID-19 vaccine generates positive pre-clinical results

Experimental vaccine begins first-in-human trial this month

J&J

An experimental vaccine candidate currently being developed by Johnson and Johnson has proved promising in early, pre-clinical studies.

The vaccine, Ad26.COV2.S, induced a robust immune response in monkeys, demonstrated by high levels of neutralising antibodies. According to J&J, this immune response successfully prevented subsequent infection and provided complete or near-complete protection from the SARS-CoV-2 virus, which causes COVID-19.

In the studies, J&J’s researchers initially immunised the animals with a number of vaccine candidates – out of seven vaccine prototypes tested in the study, scientists found that Ad26.COV2.S elicited the highest levels of neutralising antibodies to SARS-CoV-2.

All six animals that received a single immunisation with the lead vaccine candidate showed no detectable virus in their lower respiratory tract after exposure to SARS-CoV-2, and only one showed very low levels of the virus in a nasal swab at two time points.

Based on the promising results from the animal study, J&J has started a phase 1/2a human clinical trial of the vaccine trial in the US and Belgium. This clinical trial programme will evaluate both one- and two-dose regimens of Ad26.COV2.S in over 1,000 health adults aged 18 to 55 years, as well as adults aged 65 and over.

If all goes to plan in the first-in-human clinical trials, J&J hopes to begin a pivotal phase 3 trial of the single vaccine dose versus placebo in September, as well as a parallel phase 3 study of a two-dose regimen versus placebo.

The company added that it will emphasise representation of populations that have been the most impacted by the pandemic in the phase 3 trial programme. In the US, this would include significant representation of participants over 65 years of age and certain minority ethnic groups.

J&J and the US government’s Biomedical Advanced Research and Development Authority (BARDA) have collectively committed $1bn to the vaccine project, which will be spent on R&D and clinical testing of the vaccine.

“We are excited to see these pre-clinical data because they show our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose,” said Paul Stoffels, vice chairman of the executive committee and chief scientific officer, J&J.

“The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a phase 1/2a trial in July with the intention to move into a phase 3 trial in September," he added.

Article by
Lucy Parsons

31st July 2020

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....